Healthcare Facilities Increase Influenza and COVID-19 Testing Due to Ongoing Flu Season

The coronavirus (COVID-19) outbreak has sparked concern among individuals suffering from influenza. Due to similarities in symptoms, healthcare institutes are increasing awareness about the differences in symptoms. Though influenza and COVID-19 are both contagious respiratory illnesses, they are caused by different viruses. This confusion has created revenue opportunities for companies in the respiratory antiviral treatment market, since infected individuals are seeking professional help from doctors to identify the symptoms.

Influenza is a serious medical issue in western countries. A second wave of COVID-19 in European countries is likely to compromise healthcare facilities. Hence, healthcare professionals are identifying people at high risk of acquiring influenza and COVID-19, and are recommending preventive measures to minimize the pressure in healthcare facilities.

These factors are likely to drive the respiratory antiviral treatment market.

Request a sample to get extensive insights into the Respiratory Antiviral Treatment Market

RSV-associated Clinical Trails Holds Promising Potentials for Development of Bronchiolitis Antivirals

Innovations in the treatment of respiratory syncytial virus (RSV) infection hold promising potentials for the bronchiolitis treatment. For instance, Ark Biosciences— a biotech company specializing in therapeutics for viral infections and respiratory illnesses has announced a successful completion of the phase 2 proof-of-concept study for Ziresovir (AK0529), which is an antiviral agent. Bronchiolitis has led to several hundreds of thousands of deaths worldwide, especially of children under five years of age. Hence, companies in the respiratory antiviral treatment market are increasing their research capabilities to develop therapeutics for bronchiolitis in infants.

Current antiviral agents developed by companies in the respiratory antiviral treatment market are found to have clinical benefits but are not licensed by healthcare institutions. Companies are increasing efforts to develop antivirals that are effective in reducing signs and symptoms of bronchiolitis in infants.

Government-funded Grants Accelerate Development of Influenza Antivirals

Several new direct-acting influenza antivirals have been introduced in the respiratory antiviral treatment market. As such, baloxavir marboxil has been approved in the U.S., which is an antiviral for the treatment of influenza. However, there is a need to develop a universal influenza vaccine. Hence, healthcare companies are increasing their R&D capabilities to propose strategic plans ahead of government agencies with the help of field experts. On the other hand, manufacturers in the respiratory antiviral treatment market are increasing efforts to improve current seasonal influenza vaccines.

In order to tap into incremental opportunities in Europe, manufacturers are developing intravenous zanamivir-like antivirals, which is the only licensed treatment for influenza. This explains why the market is projected to expand at a CAGR of ~6% during the assessment period. Companies are achieving clinical developments in selected neuraminidase inhibitors, host-directed therapies, and selected polymerase inhibitors. Celdara Medical— a biotechnology-based company in the U.S. is gaining recognition for receiving Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop antivirals for COVID-19 and influenza.

Healthcare Providers Adopting Optimal Control Strategies to Overcome Issue of Drug Resistance

The respiratory antiviral treatment market is expected to surpass revenue of US$ 5.3 Bn by the end of 2030. However, the issue of antiviral resistance is emerging as a restraint for market growth. For instance, M2 ion-channel inhibitors and neuraminidase (NA) inhibitors are approved treatments for influenza; however, they are associated with drug resistance in individuals. As such, neuraminidase inhibitors are being used on an extensive scale as an anti-influenza drug, since this treatment is less susceptible to drug resistance.

Since drug resistance has led to increased cost of patient healthcare, companies in the respiratory antiviral treatment market are shifting their business models toward the development of vaccines to curb the spread of respiratory illnesses. Since coinfection of pneumonia and influenza has led to increased morbidity and mortality, healthcare providers are adopting optimal control strategies.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Antiviral Therapies Emerge as Alternative to Influenza Vaccines in High-risk Patients

The antiviral treatment is being highly preferred to shorten the duration of influenza symptoms. Moreover, these antivirals help to decrease the length of hospitals stays and minimizes the risk of complications in patients. As suggested by the CDC (Centers for Disease Control and Prevention), antiviral therapies help to improve medical outcomes in high-risk patients. As such, antiviral chemoprophylaxis is gaining increased popularity for influenza prevention and is being used as an adjunct to vaccination. Companies in the respiratory antiviral treatment market are boosting their output capacity to produce antiviral chemoprophylaxis meant for high-risk patients who cannot receive vaccination due to medical reasons.

Since high-risk patients such as pregnant women are susceptible to contraindications by vaccines, companies in the respiratory antiviral treatment market are increasing awareness about antiviral chemoprophylaxis to treat influenza. Patients with insufficient immune response are also recommended with antiviral chemoprophylaxis.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Respiratory Antiviral Treatment Market

Immunoglobulins with Antiviral Drugs Help Reduce Symptoms of Measles

Companies in the respiratory antiviral treatment market are innovating in antiviral drugs to treat measles. However, their effectiveness after central nervous system (CNS) manifestations remain to be evaluated. Companies in the respiratory antiviral treatment market are experimenting with immunoglobulins to treat measles infection. The combination treatment is being highly publicized for measles treatment, which involves the use of immunoglobulins with antiviral drugs to reduce signs and symptoms.

Ribavirin is a popular antiviral drug used for the treatment of measles infection. The combination of ribavirin and immune serum globulin holds promising potentials to reduce respiratory symptoms of measles. Companies are conducting clinical trials to identify whether the action of vitamin A helps in the treatment of measles. Though vaccines are considered as the most efficient prevention of against measles, the decreasing coverage combined to the increasing number of immunocompromised people difficult to vaccinate confirm the necessity to develop efficient antiviral drugs.

Analysts’ Viewpoint

Healthcare institutes are offering funding to biotech companies to develop antiviral drugs that treat influenza and COVID-19. Direct-acting influenza antivirals are being preferred by healthcare providers to minimize symptoms of respiratory illnesses in patients. However, drug resistance is emerging as a problem in healthcare settings, resulting in increased cost of hospital stay. Hence, companies in the respiratory antiviral treatment market should increase awareness about optimal control strategies such as vaccines and isolation, if patients have low immune response toward antiviral drugs. The combination treatment of immunoglobulins with antiviral drugs helps to reduce signs and symptoms of the measles infection. Ribavirin is being highly publicized as an antiviral drug for the treatment of measles.

Respiratory Antiviral Treatment Market: Overview

  • Antiviral drugs are therapeutics that prevent the development and replication of virus without affecting host cells. These drugs do not destroy their target virus, as it is an obligatory intracellular parasite. Instead, these inhibit their propagation by deactivating viral enzymes.
  • Antiviral drugs are utilized to treat various types of respiratory conditions such as influenza, bronchiolitis, upper respiratory tract infections (URTI), pneumonia, and measles due to their effectiveness
  • The global respiratory antiviral treatment market has experienced significant growth in the last decade due to rise in prevalence of respiratory viral diseases and favorable policies
  • Different types of therapeutics are used in the treatment of respiratory viral diseases, including nucleoside analogs, neuraminidase inhibitors, ion channel blockers, and fusion protein inhibitors. Neuraminidase inhibitors are most commonly used in the treatment of respiratory viral diseases.

Respiratory Antiviral Treatment: Market Drivers

  • Rise in prevalence and incidence of respiratory viral diseases such as influenza, bronchiolitis, and others drives demand for respiratory antiviral treatment. Incidence and prevalence of flu are gradually increasing across the globe. According to the CDC, around 5% to 20% of the population is affected with the flu in the U.S. every year. Additionally, an estimated 200,000 people are hospitalized due to flu infection in the country every year; of these 36,000 succumb to flu complications.
  • Favorable policies for treatment and prevention of respiratory viral diseases are projected to drive the global respiratory antiviral treatment market during the forecast period. For instance, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) publishes recommendations for high-risk groups. It offers references for use of antiviral agents for treatment and prevention of respiratory viral diseases.

Market Segmentation: Respiratory Antiviral Treatment Market

  • In terms of drug class, the global respiratory antiviral treatment market has been divided into nucleoside analogs, neuraminidase inhibitors, ion channel blockers, and fusion protein inhibitors. The nucleoside analogs segment has been split into ribavirin, acyclovir, and others. The neuraminidase inhibitors segment has been sub-divided into oseltamivir, zanamivir, and others. The neuraminidase inhibitors segment is anticipated to dominate the global respiratory antiviral treatment market during the forecast period.
  • Based on disease type, the global respiratory antiviral treatment market has been classified influenza, bronchiolitis, pneumonia, upper respiratory tract infections (URTIs), and others (measles, etc.)
  • In terms of distribution channel, the global respiratory antiviral treatment market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the global respiratory antiviral treatment market in terms of revenue in 2019.
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The report provides current and expected revenue (US$ Mn) for each of these segments from 2018 to 2030, considering 2019 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2020 to 2030, along with market size estimations.

Regional Overview: Respiratory Antiviral Treatment Market

  • The global respiratory antiviral treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • The current and expected market revenue (US$ Mn) of these regional markets and their major countries have been provided in the report from 2018 to 2030, with their CAGRs from 2020 to 2030
  • The study also offers a list of recommendations, highlights, and useful insights of the global respiratory antiviral treatment market, which would help new companies willing to enter the market and existing companies to increase market shares, and in the decision-making process

Major Players

  • The respiratory antiviral treatment market report concludes with the company profiles section, which includes key information about major players in the global respiratory antiviral treatment market
  • Leading players analyzed in the respiratory antiviral treatment market report include
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Mylan Inc.
    • Merck & Co., Inc.
    • AstraZeneca plc.
  • Each of these players has been profiled in the respiratory antiviral treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Respiratory Antiviral Treatment Market – Scope of the Report

TMR’s report on the global respiratory antiviral treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators for the market during the forecast period from 2020 to 2030. The report provides revenue of the global respiratory antiviral treatment market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the global respiratory antiviral treatment market from 2020 to 2030.

The report is prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the respiratory antiviral treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the respiratory antiviral treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global respiratory antiviral treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global respiratory antiviral treatment market.

The report delves into the competition landscape of the global respiratory antiviral treatment market. Key players operating in the global respiratory antiviral treatment market are identified and each one of these is profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global respiratory antiviral treatment market profiled in this report.

Key Questions Answered in Respiratory Antiviral Treatment Market Report

  1. What is the sales/revenue generated by respiratory antiviral treatment across all regions during the forecast period?
  2. What are the opportunities in the global respiratory antiviral treatment market?
  3. What are the major drivers, restraints, opportunities, and threats in the market?
  4. Which regional market is set to expand at the fastest CAGR during the forecast period?
  5. Which drug class segment is expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
  6. What are the market positions of different companies operating in the global market?

Respiratory Antiviral Treatment Market – Research Objectives and Research Approach

The comprehensive report on the global respiratory antiviral treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global respiratory antiviral treatment market in terms of drug class, disease type, distribution channel, and region. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2030 has also been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global respiratory antiviral treatment market.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Respiratory Antiviral Treatment Market – Segmentation

TMR’s study on the global respiratory antiviral treatment market includes information divided into four segments: drug class, disease type, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global respiratory antiviral treatment market are discussed in detail.

Drug Class

  • Nucleoside Analogs
  • Neuraminidase Inhibitors
  • Ion Channel Blockers
  • Fusion Protein Inhibitors

Disease Type

  • Influenza
  • Bronchiolitis
  • Pneumonia
  • Upper Respiratory Tract Infections (URTIs)
  • Others (Measles, etc.)

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface

    1.1. Report Scope and Market Segmentation

    1.2. Research Highlights

2. Assumptions and Research Methodology

    2.1. Assumptions and Acronyms Used

    2.2. Research Methodology

3. Executive Summary

4. Market Overview

    4.1. Introduction

    4.2. Key Industry Developments

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunity

    4.4. Global Respiratory Antiviral Treatment Market Forecast

    4.5. Global Respiratory Antiviral Treatment Market Outlook

5. Market Outlook

    5.1. Pipeline Analysis

    5.2. Disease Prevalence Rate Globally with Key Countries

    5.3. COVID-19 Impact Analysis

6. Global Respiratory Antiviral Treatment Market Analysis, by Drug Class

    6.1. Introduction

    6.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

    6.3. Global Respiratory Antiviral Treatment Market Forecast, by Drug Class

        6.3.1. Nucleoside Analogs

            6.3.1.1. Ribavirin

            6.3.1.2. Aciclovir

            6.3.1.3. Others

        6.3.2. Neuraminidase Inhibitors

            6.3.2.1. Oseltamivir

            6.3.2.2. Zanamivir

            6.3.2.3. Others

        6.3.3. Ion Channel Blockers

        6.3.4. Fusion Protein Inhibitors

    6.4. Global Respiratory Antiviral Treatment Market Analysis, by Drug Class

7. Global Respiratory Antiviral Treatment Market Analysis, by Disease Type

    7.1. Introduction

    7.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

    7.3. Global Respiratory Antiviral Treatment Market Forecast, by Disease Type

        7.3.1. Influenza

        7.3.2. Bronchiolitis

        7.3.3. Pneumonia

        7.3.4. Upper Respiratory Tract Infections (URTIs)

        7.3.5. Others (measles, etc.)

    7.4. Global Respiratory Antiviral Treatment Market Analysis, by Disease Type

8. Global Respiratory Antiviral Treatment Market Analysis, by Distribution Channel

    8.1. Introduction

    8.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    8.3. Global Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Global Respiratory Antiviral Treatment Market Analysis, by Route of Administration

9. Global Respiratory Antiviral Treatment Market Analysis, by Region

    9.1. Global Respiratory Antiviral Treatment Market Scenario, by Region/Country

    9.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Region

    9.3. Global Respiratory Antiviral Treatment Market Forecast, by Region

        9.3.1. North America

        9.3.2. Europe

        9.3.3. Asia Pacific

        9.3.4. Latin America

        9.3.5. Middle East & Africa

10. North America Respiratory Antiviral Treatment Market Analysis

    10.1. North America Respiratory Antiviral Treatment Market Overview

    10.2. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country

    10.3. North America Respiratory Antiviral Treatment Market Forecast, by Country

        10.3.1. U.S.

        10.3.2. Canada

    10.4. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

    10.5. North America Respiratory Antiviral Treatment Market Forecast, by Drug Class

        10.5.1. Nucleoside Analogs

            10.5.1.1. Ribavirin

            10.5.1.2. Aciclovir

            10.5.1.3. Others

        10.5.2. Neuraminidase Inhibitors

            10.5.2.1. Oseltamivir

            10.5.2.2. Zanamivir

            10.5.2.3. Others

        10.5.3. Ion Channel Blockers

        10.5.4. Fusion Protein Inhibitors

    10.6. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

    10.7. North America Respiratory Antiviral Treatment Market Forecast, by Disease Type

        10.7.1. Influenza

        10.7.2. Bronchiolitis

        10.7.3. Pneumonia

        10.7.4. Upper Respiratory Tract Infections (URTIs)

        10.7.5. Others (measles, etc.)

    10.8. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    10.9. North America Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

        10.9.1. Hospital Pharmacies

        10.9.2. Retail Pharmacies

        10.9.3. Online Pharmacies

11. Europe Respiratory Antiviral Treatment Market Analysis

    11.1. Europe Respiratory Antiviral Treatment Market Overview

    11.2. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

    11.3. Europe Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region

        11.3.1. Germany

        11.3.2. France

        11.3.3. U.K.

        11.3.4. Italy

        11.3.5. Spain

        11.3.6. Rest of Europe

    11.4. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

    11.5. Europe Respiratory Antiviral Treatment Market Forecast, by Drug Class

        11.5.1. Nucleoside Analogs

            11.5.1.1. Ribavirin

            11.5.1.2. Aciclovir

            11.5.1.3. Others

        11.5.2. Neuraminidase Inhibitors

            11.5.2.1. Oseltamivir

            11.5.2.2. Zanamivir

            11.5.2.3. Others

        11.5.3. Ion Channel Blockers

        11.5.4. Fusion Protein Inhibitors

    11.6. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

    11.7. Europe Respiratory Antiviral Treatment Market Forecast, by Disease Type

        11.7.1. Influenza

        11.7.2. Bronchiolitis

        11.7.3. Pneumonia

        11.7.4. Upper Respiratory Tract Infections (URTIs)

        11.7.5. Others (measles, etc.)

    11.8. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    11.9. Europe Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

        11.9.1. Hospital Pharmacies

        11.9.2. Retail Pharmacies

        11.9.3. Online Pharmacies

12. Asia Pacific Respiratory Antiviral Treatment Market Analysis

    12.1. Asia Pacific Respiratory Antiviral Treatment Market Overview

    12.2. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

    12.3. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region

        12.3.1. Japan

        12.3.2. China

        12.3.3. India

        12.3.4. Australia & New Zealand

        12.3.5. Rest of Asia Pacific

    12.4. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

    12.5. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Drug Class

        12.5.1. Nucleoside Analogs

            12.5.1.1. Ribavirin

            12.5.1.2. Aciclovir

            12.5.1.3. Others

        12.5.2. Neuraminidase Inhibitors

            12.5.2.1. Oseltamivir

            12.5.2.2. Zanamivir

            12.5.2.3. Others

        12.5.3. Ion Channel Blockers

        12.5.4. Fusion Protein Inhibitors

    12.6. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

    12.7. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Disease Type

        12.7.1. Influenza

        12.7.2. Bronchiolitis

        12.7.3. Pneumonia

        12.7.4. Upper Respiratory Tract Infections (URTIs)

        12.7.5. Others (measles, etc.)

    12.8. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    12.9. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

        12.9.1. Hospital Pharmacies

        12.9.2. Retail Pharmacies

        12.9.3. Online Pharmacies

13. Latin America Respiratory Antiviral Treatment Market Analysis

    13.1. Latin America Respiratory Antiviral Treatment Market Overview

    13.2. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

    13.3. Latin America Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region

        13.3.1. Brazil

        13.3.2. Mexico

        13.3.3. Rest of Latin America

    13.4. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

    13.5. Latin America Respiratory Antiviral Treatment Market Forecast, by Drug Class

        13.5.1. Nucleoside Analogs

            13.5.1.1. Ribavirin

            13.5.1.2. Aciclovir

            13.5.1.3. Others

        13.5.2. Neuraminidase Inhibitors

            13.5.2.1. Oseltamivir

            13.5.2.2. Zanamivir

            13.5.2.3. Others

        13.5.3. Ion Channel Blockers

        13.5.4. Fusion Protein Inhibitors

    13.6. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

    13.7. Latin America Respiratory Antiviral Treatment Market Forecast, by Disease Type

        13.7.1. Influenza

        13.7.2. Bronchiolitis

        13.7.3. Pneumonia

        13.7.4. Upper Respiratory Tract Infections (URTIs)

        13.7.5. Others (measles, etc.)

    13.8. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    13.9. Latin America Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

        13.9.1. Hospital Pharmacies

        13.9.2. Retail Pharmacies

        13.9.3. Online Pharmacies

14. Middle East & Africa Respiratory Antiviral Treatment Market Analysis

    14.1. Middle East & Africa Respiratory Antiviral Treatment Market Overview

    14.2. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

    14.3. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region

        14.3.1. GCC Countries

        14.3.2. South Africa

        14.3.3. Rest of Middle East & Africa

    14.4. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

    14.5. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Drug Class

        14.5.1. Nucleoside Analogs

            14.5.1.1. Ribavirin

            14.5.1.2. Aciclovir

            14.5.1.3. Others

        14.5.2. Neuraminidase Inhibitors

            14.5.2.1. Oseltamivir

            14.5.2.2. Zanamivir

            14.5.2.3. Others

        14.5.3. Ion Channel Blockers

        14.5.4. Fusion Protein Inhibitors

    14.6. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

    14.7. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Disease Type

        14.7.1. Influenza

        14.7.2. Bronchiolitis

        14.7.3. Pneumonia

        14.7.4. Upper Respiratory Tract Infections (URTIs)

        14.7.5. Others (measles, etc.)

    14.8. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    14.9. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

        14.9.1. Hospital Pharmacies

        14.9.2. Retail Pharmacies

        14.9.3. Online Pharmacies

15. Competition Landscape

    15.1. Competition Matrix

    15.2. Company Profiles

        15.2.1. F. Hoffmann-La Roche Ltd.

            15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.1.2. Financial Overview

            15.2.1.3. Product Portfolio

            15.2.1.4. SWOT Analysis

            15.2.1.5. Strategic Overview

        15.2.2. Novartis AG

            15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.2.2. Financial Overview

            15.2.2.3. Product Portfolio

            15.2.2.4. SWOT Analysis

            15.2.2.5. Strategic Overview

        15.2.3. Takeda Pharmaceutical Company Limited

            15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.3.2. Financial Overview

            15.2.3.3. Product Portfolio

            15.2.3.4. SWOT Analysis

            15.2.3.5. Strategic Overview

        15.2.4. Pfizer, Inc.

            15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.4.2. Product Portfolio

            15.2.4.3. SWOT Analysis

            15.2.4.4. Strategic Overview

        15.2.5. Teva Pharmaceutical Industries Ltd.

            15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.5.2. Financial Overview

            15.2.5.3. Product Portfolio

            15.2.5.4. SWOT Analysis

            15.2.5.5. Strategic Overview

        15.2.6. Sun Pharmaceutical Industries Ltd.

            15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.6.2. Financial Overview

            15.2.6.3. Product Portfolio

            15.2.6.4. SWOT Analysis

            15.2.6.5. Strategic Overview

        15.2.7. GlaxoSmithKline plc

            15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.7.2. Financial Overview

            15.2.7.3. Product Portfolio

            15.2.7.4. SWOT Analysis

            15.2.7.5. Strategic Overview

        15.2.8. Mylan, Inc.

            15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.8.2. Financial Overview

            15.2.8.3. Product Portfolio

            15.2.8.4. SWOT Analysis

            15.2.8.5. Strategic Overview

        15.2.9. Merck & Co., Inc.

            15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.9.2. Financial Overview

            15.2.9.3. Product Portfolio

            15.2.9.4. SWOT Analysis

            15.2.9.5. Strategic Overview

        15.2.10. AstraZeneca plc.

            15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.10.2. Financial Overview

            15.2.10.3. Product Portfolio

            15.2.10.4. SWOT Analysis

            15.2.10.5. Strategic Overview

List of Tables

Table 01: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 02: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 03: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 04: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 05: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 06: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 07: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 08: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 09: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 10: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 11: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 12: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 13: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 14: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 15: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 16: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 17: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 18: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 19: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 20: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 21: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 22: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 23: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 24: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 25: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 26: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 27: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 28: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 29: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 30: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 31: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 32: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 33: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

Table 34: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

Table 35: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

Table 36: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

List of Figures

Figure 01: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, 2018–2030

Figure 02: Global Respiratory Antiviral Treatment Market Value Share, by Drug Class, 2019

Figure 03: Global Respiratory Antiviral Treatment Market Value Share, by Distribution Channel, 2019

Figure 04: Global Respiratory Antiviral Treatment Market Value Share, by Disease Type, 2019

Figure 05: Global Respiratory Antiviral Treatment Market Value Share, by Region, 2019

Figure 06: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 07: Global Respiratory Antiviral Treatment Market Attractiveness, by Drug Class, 2020–2030

Figure 08: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Nucleoside Analogs, 2018–2030

Figure 09: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Neuraminidase Inhibitors, 2018–2030

Figure 10: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Ion Channel Blockers, 2018–2030

Figure 11: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Fusion Protein Inhibitors, 2018–2030

Figure 12: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 13: Global Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 14: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Influenza, 2018–2030

Figure 15: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Bronchiolitis, 2018–2030

Figure 16: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Pneumonia, 2018–2030

Figure 17: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Upper Respiratory Tract Infections (URTIs), 2018–2030

Figure 18: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Others (Measles, etc.), 2018–2030

Figure 19: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 20: Global Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 21: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2018–2030

Figure 22: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2018–2030

Figure 23: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2018–2030

Figure 24: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Region, 2019 and 2030

Figure 25: Global Respiratory Antiviral Treatment Market Attractiveness Analysis, by Region

Figure 26: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 27: North America Respiratory Antiviral Treatment Market Value Share (%), by Country, 2019 and 2030

Figure 28: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country, 2020–2030

Figure 29: North America Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 30: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 31: North America Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 32: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 33: North America Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 34: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 35: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 36: Europe Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 37: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 38: Europe Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 39: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 40: Europe Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 41: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 42: Europe Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 43: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 44: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 45: Asia Pacific Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 46: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 47: Asia Pacific Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 48: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 49: Asia Pacific Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 50: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 51: Asia Pacific Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 52: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 53: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 54: Latin America Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 55: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 56: Latin America Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 57: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 58: Latin America Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 59: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 60: Latin America Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 61: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 62: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 63: Middle East & Africa Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 64: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 65: Middle East & Africa Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 66: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 67: Middle East & Africa Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

Figure 68: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

Figure 69: Middle East & Africa Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 70: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Respiratory Antiviral Treatment Market